Program
Chikungunya vaccine
Also written as “VLA1553”, “VLA1553 full dose” and “VLA1553 half dose”.
Its studies are mostly in Chikungunya Fever, led by Valneva.
Furthest: phase 3, since Sep 4, 20206 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Valneva | 61 open or running | phase 3since Sep 4, 2020 | Dec 12, 2017 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 12, 2017First study: phase 1 study in Chikungunya FeverFirst studyNCT03382964 · 120 enrolled · United States
- Sep 4, 2020Phase 3 study in Chikungunya FeverNCT04546724 · 4,128 enrolled · United States
- Apr 6, 2021Phase 3 study in Chikungunya FeverNCT04838444 · 363 enrolled · United States
- Mar 29, 2023Phase 3 study in Chikungunya FeverNCT06028841
- Oct 24, 2023Phase 2 study in Chikungunya FeverNCT06106581 · 304 enrolled · Dominican Republic, Honduras
- Aug 13, 2025Phase 3 study in Chikungunya FeverNCT07133178
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07133178Chikungunya Fever | 3 | Withdrawn | Dec 2026 | 0 |
| NCT06106581Chikungunya Fever · Dominican Republic, Honduras | 2 | Completed | Jul 31, 2024 | 304 |
| NCT06028841Chikungunya Fever | 3 | Withdrawn | Aug 27, 2024 | 0 |
| NCT04838444Chikungunya Fever · United States | 3 | Active, not recruiting | Mar 3, 2023 | 363 |
| NCT04546724Chikungunya Fever · United States | 3 | Completed | May 19, 2021 | 4,128 |
| NCT03382964Chikungunya Fever · United States | 1 | Completed | Jul 13, 2018 | 120 |
How it is read
Names in the registry
- “VLA1553”, 5 entries
- “VLA1553 full dose”, 1 entry
- “VLA1553 half dose”, 1 entry
Conditions, from the studies’ own filings
- Chikungunya Fever, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.